Company news

Organon & Co. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

May 27, 2025

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

April 15, 2025

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

April 15, 2025

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

April 1, 2025

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

March 28, 2025

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

March 8, 2025

← Newer news releases

Calls

The 5 newest of 19 calls. Every call is listed under its year.

Decks

The 5 newest of 24 decks. Every deck is listed under its year.